Mind Medicine (MindMed) (OTCMKTS:MMEDF) Shares Up 9% – Here’s What Happened

Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDFGet Free Report) shot up 9% during trading on Thursday . The company traded as high as $20.69 and last traded at $20.60. 3,219,278 shares changed hands during trading, a decline of 5% from the average session volume of 3,376,665 shares. The stock had previously closed at $18.90.

Mind Medicine (MindMed) Stock Up 9.0%

The stock has a 50 day moving average of $17.31 and a two-hundred day moving average of $14.08.

Mind Medicine (MindMed) Company Profile

(Get Free Report)

Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.

Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.

Featured Stories

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.